Deploy AI-powered pharma marketing operations on AWS with security, scale and control

For pharmaceutical organizations, the question is no longer whether generative AI can produce marketing content. The real question is whether AI-powered content operations can run securely, observably and compliantly in production. That is the threshold technical decision-makers care about when moving from pilot programs to enterprise deployment.

Publicis Sapient addresses that challenge with Bodhi, an enterprise-scale agentic AI platform, and AskBodhi, a SaaS-based API approach used to accelerate personalized content generation in regulated environments. Together with AWS, this creates a production-ready operating model for pharma marketing: one that supports compliant-ready copy and imagery generation, localization, translation, repurposing and campaign execution while aligning to enterprise security, governance and interoperability requirements.

In pharmaceutical marketing, content is not just creative output. It is regulated communication that must pass through medical, legal and brand review, reflect local market requirements, protect sensitive data and remain traceable across its lifecycle. That means generation quality alone is not enough.

When organizations scale across hundreds of brands, channels and markets, fragmented workflows quickly become the real bottleneck. Briefing, copywriting, image generation, translation, review and publishing often happen across disconnected systems with limited visibility. The result is slower time-to-market, duplicated effort, expensive localization cycles and growing governance risk.

A production-grade platform has to solve for more than output. It has to orchestrate the workflow around the output. That is why secure deployment, interoperability and observability matter as much as generation quality. Without them, AI remains a point solution. With them, AI becomes an operating model.

Publicis Sapient uses Bodhi to move organizations from fragmented production toward a governed, AI-assisted content supply chain. Bodhi is designed to help enterprises develop, deploy and scale AI solutions with speed, efficiency and security. In pharmaceutical marketing, that means supporting the full journey from campaign intent to compliant, market-ready assets.

Its capabilities span automated generation of personalized content for healthcare professionals, patients and caregivers; localization and translation for regional replication; repurposing of banners, emails and digital assets; image recommendations; multimodal content support; and end-to-end campaign generation. Just as important, Bodhi embeds guardrails, auditability and human-in-the-loop review into the workflow so governance is not treated as a late-stage fix.

This model has already delivered measurable impact for a leading global pharmaceutical company. Publicis Sapient deployed a Bodhi-powered generative AI marketing solution to transform content creation at scale, helping the organization support global personalization across more than 250 brands and diverse audiences. The outcome included up to 75% faster content production, 35% to 45% cost reduction on select content creation tasks and faster time-to-market.

Technical leaders in healthcare and life sciences rarely want a one-size-fits-all operating model. Deployment flexibility matters because security, privacy and governance expectations vary by organization, market and use case.

Publicis Sapient supports both SaaS-based API consumption through AskBodhi and client-hosted deployment patterns for Bodhi-based solutions. That flexibility is critical in regulated environments where some organizations want the speed of API-based integration, while others require solutions hosted within their own environment for tighter control over data, access, workflow orchestration and enterprise governance.

In client-hosted models, Bodhi can operate within the client’s architecture while integrating with existing marketing, compliance and data ecosystems. This enables organizations to operationalize AI without creating a disconnected stack. It also helps align the platform to internal security controls, privacy expectations and traceability requirements from the outset.

AWS provides the cloud foundation that allows Bodhi to scale from isolated use cases to production-grade content operations.

At the orchestration layer, Amazon EKS supports scalable execution of containerized AI workloads. This is important for multi-step content workflows that include generation, refinement, translation, review support and downstream asset preparation. EKS enables elastic scaling and reliable execution as campaign volumes, localization demands and asset types increase.

For model access, Amazon Bedrock provides foundation model connectivity across text and image generation and refinement workflows. In Publicis Sapient’s pharma marketing architecture, Bedrock has supported models such as Claude Haiku and Claude Sonnet for content generation, translation, prompt refinement, classification and image recommendation workflows. This gives enterprises a governed way to access model capabilities within a broader cloud architecture rather than building bespoke model integrations for every use case.

Secure connectivity patterns are equally important. In deployed architectures, services such as Amazon CloudFront, API Gateway and VPC help create controlled access paths between users, APIs and backend services. One proven pattern routes traffic through CloudFront and API Gateway into a protected VPC environment, where a network load balancer can direct requests to microservices running on Amazon EKS, managed through an ingress layer and FastAPI-based services. This allows teams to support performance, protected integration and resilient operations without exposing internal workloads directly.

Additional AWS services strengthen the enterprise control plane. IAM, GuardDuty, Macie, Cognito and WAF help protect data, enforce access controls and support compliance and governance requirements. Amazon OpenSearch Service supports indexing, search and analysis of generated content, while embeddings models and a vector database approach using AWS Aurora can improve similarity search, recommendations and reuse of approved assets.

In regulated marketing, even the best AI workflow will fail if it cannot connect to the systems already governing content, data and review. That is why interoperability is not a secondary concern. It is a design principle.

Publicis Sapient’s API-based architecture allows Bodhi and AskBodhi to integrate with existing marketing platforms, MLR workflows, content systems and data environments. This helps organizations modernize incrementally rather than forcing a rip-and-replace approach. It also reduces operational disruption, which is often one of the largest barriers to enterprise adoption.

For pharma teams, that means AI-generated content can fit into established approval paths, connect to audience and campaign data, and move more smoothly into publishing environments. For CIOs and enterprise architects, it means AI can be introduced as part of the broader platform ecosystem rather than as an unmanaged side tool.

As AI initiatives move from experimentation to production, observability becomes essential. Enterprises need visibility into workflow progress, outputs, model-supported decisions, approvals and operational performance. Without that transparency, it becomes difficult to govern the system, improve quality or demonstrate accountability.

Bodhi is designed to support observability, traceability and operational transparency across the content pipeline. In regulated environments, this visibility gives marketing, compliance and technology teams a shared basis for trust. It also supports version control, auditability and clearer accountability over where human oversight was applied.

That is especially important in pharmaceutical marketing, where the goal is not to remove human review but to make it more efficient and targeted. Guardrails and automated checks can shift compliance earlier into the workflow, while human reviewers focus on judgment, nuance and high-stakes approval.

For pharmaceutical companies, moving from GenAI pilot to production is ultimately an architectural decision as much as a creative one. The winners will not be the organizations that simply generate more content. They will be the ones that can orchestrate content operations securely, integrate them into enterprise workflows, localize at scale and maintain clear governance across the full lifecycle.

With Bodhi on AWS, Publicis Sapient helps make that possible. The result is a production-grade platform for regulated marketing: secure in deployment, interoperable by design, observable in operation and scalable enough to support compliant personalization across global markets. That is how AI-powered pharma marketing moves from experimentation to enterprise value.

Relevant Links

• Pharmaceutical Company Scales Marketing with GenAI
• Pharmaceutical Company Scales Marketing with GenAI
• Pharmaceutical marketing leaders do not need another isolated AI feature. They need a better operating model.
• Turn medical, legal and regulatory review from a bottleneck into a business accelerator
• Global-to-Local Content Activation for Pharmaceutical Marketing
• IA generativa para el marketing farmacéutico en México: cómo escalar personalización, velocidad y cumplimiento sin multiplicar la complejidad (LATAM)
• FAQ (FAQ)
• FAQ (FAQ)
• What to Know About Publicis Sapient’s Generative AI Approach for Pharmaceutical Marketing: 10 Key Facts (LIST)
• What to Know About Publicis Sapient’s Generative AI Approach for Pharmaceutical Marketing: 10 Key Facts (LIST)
• L’IA générative au service du marketing pharmaceutique en Europe (Europe)